Clinical Trial Update: A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Licartin to prevent tumor recurrence after liver resection in hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Licartin (Iodine-131 metaiodobenzylguanidine)

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED